Cetilistate

  Referências :

 

1. Padwal R. Cetilistat, a new lipase inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2008;9(4):414-21.

 

2. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring). 2010;18(1):108-15.

 

3. WHO — Obesity and Overweight in Report of WHO Consultation on Obesity. Geneva : World Health Organization, 2011.

 

4. Jain SS, Ramanand SJ, Ramanand JB, Akat PB, Patwardhan MH, Joshi SR. Evaluation of efficacy and safety of orlistat in obese patients. Indian J Endocrinol Metab. 2011 Apr;15(2):99-104

 

5. FARIA, A. M et AL., Progressos recentes e novas perspectivas em farmacoterapia da obesidade. Arq Bras Endocrinol Metab.
54/6, 2010.